A pioneering cancer drug set to become the first to be approved specifically for inherited cancers could also be used much more widely to treat prostate cancer, a world-leading expert has said. Delegates at the UK’s leading annual cancer conference heard that olaparib, which last month was recommended for approval for women with ovarian cancer and inherited BRCA mutations, is also showing promise in advanced prostate cancer.

Professor Johann de Bono, leader of a succession of major international prostate cancer trials, told the National Cancer Research Institute (NCRI) Cancer Conference in Liverpool that the PARP inhibitor olaparib could be effective against prostate tumours that harboured particular gene mutations, even where the damaged genes were not inherited.

READ FULL ARTICLE Curated publisher From Medical News Today